ESMO 2016: Early Results for Pembrolizumab Against Metastatic Enzalutamide-Refractory Prostate Cancer

Article

Pembrolizumab showed clinical activity against some cases of enzalutamide-refractory metastatic castration-resistant prostate cancer.

Pembrolizumab (Keytruda) showed clinical activity against some cases of enzalutamide (Xtandi)-refractory metastatic castration-resistant prostate cancer (mCRPC), according to preliminary findings from a small phase II trial presented (abstract 719O)  at the European Society for Medical Oncology (ESMO) Congress, held October 7-11, 2016, in Copenhagen, Denmark.

The findings are the first evidence of significant clinical activity against mCRPC for programmed cell death protein 1 (PD-1) immune checkpoint blockade, they researchers wrote.

“Early results demonstrate reproducible, profound and – to date – durable responses to PD-1 inhibition with enzalutamide in men with mCRPC,” wrote lead study author Julie N. Graff, MD, of the Knight Cancer Institute, Oregon Health & Science University in Portland, and coauthors.

The potential of immunotherapies like immune checkpoint blockade in treating prostate cancer has been unclear, but increased PD ligand 1 (PD-L1) expression is associated with tumor resistance to enzalutamide, the researchers noted. Androgen inhibition also affects immune response to prostate tumors.

They therefore sought to determine whether or not adding a PD-1 inhibitor, pembrolizumab, to enzalutamide yields antitumor activity.

“We treated men with mCRPC progressing on the androgen receptor antagonist enzalutamide on a phase II study of pembrolizumab 200 mg IV every 3 weeks for 4 doses with continued enzalutamide,” they reported. Patients with prior mCRPC-directed chemotherapy were excluded from the study.

As of July 22, 2016, at a median follow-up of 18 weeks, 20 patients had completed pembrolizumab, of whom four (20%) achieved a confirmed PSA reduction of 50% or more, serum PSA < 0.1 ng/ml, and had remained progression-free after 16 to 61 weeks. Seven other patients have had stable disease (SD) for 9 to 50 weeks. Eight patients experienced disease progression.

“Two of the responders were able to discontinue opioid analgesic after reporting resolution of cancer-related pain,” the authors noted.

Five patients (25%) experienced significant immune-related adverse events. (Two patients developed grade 3 colitis; one patient each experienced grade 2 myositis, grade 2 hypothyroidism, and grade 3 hypothyroidism.)

Immunohistochemical analysis from pretreatment biopsies were possible for two responders, revealing CD3+, CD8+, and CD163+ leukocyte infiltrates and PD-L1 expression.

The study was funded by Merck Sharp & Dohme Corporation.

 

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content